Innovation Day: Celebrating Innovation Excellence
Post Date: February 10, 2022 | Publish Date:
Cincinnati Children’s Innovation Ventures is observing Innovation Day on Feb. 15, 2022, to celebrate the pursuit of innovation at Cincinnati Children’s.
Innovation is a key component of our origin story. The medical center has become one of the world’s premier children’s hospitals not only because of our compassionate care, but also thanks to historic breakthrough discoveries and collaborations with industry who developed such discoveries into products.
Innovation Day begins with a livestreamed panel discussion with those individuals who advanced a discovery towards a license to Kurome Therapeutics. The collaboration is a case study for working with Cincinnati Children’s Innovation Ventures. The panel will include:
- Abram Gordon, JD, VP of Cincinnati Children’s Innovation Ventures
- Dan Starczynowski, PhD, Professor, Katherine Stewart Waters Endowed Chair of Hematologic Malignancies, Cincinnati Children’s; Co-Chief Scientific Officer, Innovation Ventures; Founder, Kurome Therapeutics
- Jan Rosenbaum, PhD, CEO and President, Kurome Therapeutics
- Mike Venerable, CEO and Managing Director, CincyTech
Immediately following the panel discussion will be the Innovation Excellence Awards ceremony, led by Tina Cheng, MD, MPH, B.K. Rachford Memorial Chair in Pediatrics, Chief Medical Officer, and Research Foundation Director.
Innovation Excellence Award recipients
Sarah Beal, PhD, from the Division of Behavioral Medicine & Clinical Psychology for IDENTITY
Ron Bryson from the Division of Biomedical Informatics for network-based Learning Health System architecture
Lee Denson, MD, from the Division of Gastroenterology Hepatology and Nutrition for dosing and pilot efficacy of 2’-Fucosyllactose in pediatric inflammatory bowel disease
Judith Dexheimer, PhD, from the Division of Biomedical Informatics and Emergency Medicine for IDENTITY
Craig Erickson, MD, from the Division of Psychiatry for the repurpose of an investigational drug for Fragile X Syndrome, and for an adeno-associated viral based gene therapy for Fragile X Syndrome
Katrina Fields, BSN, RN, from the Heart Institute for Ventricular Assist Device learning platform
Mary Greiner, MD, MS, from the Division of General and Community Pediatrics for IDENTITY
Christina Gross, PhD, from the Division of Neurology for an adeno-associated viral based gene therapy for Fragile X Syndrome
Andrew Hershey, MD, PhD, FAHS, from the Division of Neurology for PedMIDAS
Kevin Hommel, PhD, from the Division of Behavioral Medicine & Clinical Psychology for Migraine Manager
Xi Jason Jiang, PhD, from the Division of Infectious Diseases for a novel, virus-like particle vaccine platform
Carole Lannon, MD, MPH, from the James M. Anderson Center for Health Systems Excellence for network-based Learning Health System architecture
Stephanie Loos, PMP, from the Division of Biomedical Informatics for network-based Learning Health System architecture
Angela Lorts, MD, MBA, from the Heart Institute for Ventricular Assist Device learning platform
Peter Margolis, MD, PhD, from the James M. Anderson Center for Health Systems Excellence for network-based Learning Health System architecture
Ardythe Morrow, PhD, from Division of Reproductive Sciences for dosing and pilot efficacy of 2’-Fucosyllactose in pediatric inflammatory bowel disease
Stephen Muething, MD, from the James M. Anderson Center for Health Systems Excellence for network-based Learning Health System architecture
Jeremy Nix from the Division of Biomedical Informatics for network-based Learning Health System architecture
Ernest Pedapati, MD, MS, FAAP, from the Division of Psychiatry for an adeno-associated viral based gene therapy for Fragile X Syndrome
Michael Seid, PhD, from Division of Pulmonary Medicine for network-based Learning Health System architecture
William Shuman from the Division of Biomedical Informatics for network-based Learning Health System architecture
Lauren Smyth, MHA, from the Heart Institute for Ventricular Assist Device learning platform
Daniel Starczynowski, PhD, from the Cancer & Blood Diseases Institute for adaptive resistance discovery in IRAK1 and IRAK4 inhibitors
Ming Tan, PhD, from the Division of Infectious Diseases for a novel, virus-like particle vaccine platform
